Overall Survival with Amivantamab–Lazertinib in EGFR-Mutated Advanced NSCLC
Source: View publication →
In patients with previously untreated EGFR-mutated advanced non-small cell lung cancer, the combination of amivantamab and lazertinib significantly improved overall survival compared to osimertinib monotherapy.
Key Findings
Study Design
Study Limitations
Clinical Significance
This study establishes amivantamab–lazertinib as a chemotherapy-free, first-line standard-of-care option for patients with EGFR-mutated metastatic NSCLC, offering a clear survival benefit, though it requires robust management of treatment-related toxicities.
Historical Context
Third-generation EGFR tyrosine kinase inhibitors like osimertinib previously defined the first-line treatment landscape for EGFR-mutated NSCLC; however, inevitable resistance necessitated the investigation of dual inhibition (e.g., targeting both EGFR and MET) to improve durability of response and survival.
Guided Discussion
High-yield insights from every perspective
Amivantamab is a bispecific antibody targeting both EGFR and MET. Why is targeting MET simultaneously particularly important in the context of treating EGFR-mutated non-small cell lung cancer?
Key Response
MET amplification is a common mechanism of acquired resistance to third-generation EGFR tyrosine kinase inhibitors (TKIs) like osimertinib. By targeting both receptors from the start, the combination of amivantamab and lazertinib aims to delay or prevent the emergence of MET-driven resistance clones, leading to more durable responses.
The MARIPOSA trial reported a higher incidence of venous thromboembolism (VTE) in the amivantamab–lazertinib group compared to the osimertinib group. What are the clinical implications for patient monitoring and prophylaxis when initiating this combination therapy?
Key Response
In MARIPOSA, VTE occurred in approximately 10% of patients in the combination arm. Clinicians must be vigilant for signs of DVT/PE, and current protocols (including the trial's updated safety measures) often recommend prophylactic anticoagulation (e.g., with LMWH or DOACs) for the first four months of treatment to mitigate this specific risk.
While the MARIPOSA trial demonstrated superior progression-free survival (PFS) and overall survival (OS) for the combination, osimertinib remains the standard for many due to its CNS penetration. How does the intracranial activity of the amivantamab–lazertinib combination compare to osimertinib monotherapy in patients with baseline brain metastases?
Key Response
Lazertinib is a highly CNS-penetrant third-generation TKI similar to osimertinib. Subgroup analyses from MARIPOSA suggest that the combination maintains intracranial efficacy comparable to osimertinib, addressing concerns that the larger amivantamab molecule might not provide additional CNS protection while ensuring the TKI component still covers the 'sanctuary site' of the brain.
Given the overall survival benefit reported in the MARIPOSA trial, how should the trade-off between increased efficacy and the logistical burden of bi-weekly infusions and infusion-related reactions (IRRs) influence the shared decision-making process for a newly diagnosed patient?
Key Response
The OS benefit (HR 0.80) establishes a new efficacy benchmark, but the combination requires intravenous access, frequent clinic visits for amivantamab infusions, and carries a high IRR rate (approx. 63% on first dose). For elderly patients or those with poor performance status, the oral convenience and lower toxicity profile of osimertinib may still outweigh the survival gains of the combination.
Scholarly Review
Critical appraisal through the lens of expert reviewers and guideline development
The MARIPOSA trial utilizes a 1:1:1 randomization including a lazertinib monotherapy arm. What is the statistical and biological rationale for including this third arm, and how does it strengthen the interpretation of the amivantamab–lazertinib synergy?
Key Response
Including lazertinib monotherapy allows researchers to isolate the contribution of amivantamab. It proves that the observed superiority over osimertinib is due to the combination's synergistic bispecific targeting and ADCC activity rather than lazertinib simply being a more potent TKI than osimertinib, thereby validating the biological hypothesis of dual-pathway inhibition.
In the MARIPOSA trial, the control arm was osimertinib monotherapy, which is the established global standard. However, considering the primary endpoint was PFS and the secondary was OS, how might the lack of a mandatory crossover to amivantamab upon progression in the osimertinib arm affect the purity of the OS signal?
Key Response
If control-group patients do not have access to amivantamab-based regimens at progression (which reflect the 'best possible' subsequent care), the OS benefit might be inflated by the difference in access to potent salvage therapies rather than the front-line combination itself. Editors must scrutinize the 'post-progression therapy' data to ensure the OS advantage is truly intrinsic to the first-line setting.
Should the NCCN and ESMO guidelines elevate amivantamab–lazertinib to a 'Preferred' (Category 1) status alongside osimertinib for first-line EGFR-mutant NSCLC, or does the safety profile warrant a 'Useful in Certain Circumstances' designation?
Key Response
Current NCCN guidelines highly value osimertinib for its ease of use and safety. While MARIPOSA provides Level 1 evidence for OS improvement, the Guideline Committee must weigh this against the Grade 3+ adverse event rate (75% vs 28% for osimertinib). A 'Preferred' status is likely given the OS data, but with specific caveats regarding VTE prophylaxis and the management of dermatologic toxicities that are significantly more prevalent with the combination.
Clinical Landscape
Noteworthy Related Trials
FLAURA Trial
Tested
Osimertinib
Population
Untreated EGFR-mutated advanced NSCLC
Comparator
Gefitinib or Erlotinib
Endpoint
Progression-free survival
CHRYSALIS Trial
Tested
Amivantamab
Population
EGFR Exon 20 insertion-mutated NSCLC progressing after platinum-based chemotherapy
Comparator
None (single-arm)
Endpoint
Overall response rate
FLAURA2 Trial
Tested
Osimertinib plus platinum-pemetrexed chemotherapy
Population
Untreated EGFR-mutated advanced NSCLC
Comparator
Osimertinib monotherapy
Endpoint
Progression-free survival
Tailored to your role
Want this tailored to you?
Add your specialty or training stage to get role-specific takeaways and more questions.
Personalize this analysis